Norges Bank
CRSP icon

Norges Bank’s CRISPR Therapeutics CRSP Stock Holding History

Norges Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-270,756
Closed -$14.8M – 339
2026
Q2 		$14.8M Buy
+270,756
New +$14.3M ﹤0.01% 1247
2026
Q1 		– Sell
-490,206
Closed -$25.7M – 340
2025
Q4 		$25.7M Buy
490,206
+6,868
+1% +$411K ﹤0.01% 1193
2025
Q3 		$31.3M Buy
483,338
+76,851
+19% +$4.41M ﹤0.01% 1124
2025
Q2 		$19.8M Sell
406,487
-49,573
-11% -$1.92M ﹤0.01% 1190
2025
Q1 		$15.5M Buy
456,060
+12,524
+3% +$531K ﹤0.01% 1227
2024
Q4 		$17.5M Buy
443,536
+31,928
+8% +$1.51M ﹤0.01% 1254
2024
Q3 		$19.3M Sell
411,608
-238,600
-37% -$12.1M ﹤0.01% 1230
2024
Q2 		$35.1M Buy
650,208
+59,940
+10% +$3.47M 0.01% 1050
2024
Q1 		$40.2M Sell
590,268
-27,318
-4% -$1.96M 0.01% 1041
2023
Q4 		$38.7M Buy
617,586
+31,286
+5% +$1.73M 0.01% 1024
2023
Q3 		$26.6M Buy
586,300
+9,267
+2% +$479K 0.01% 1113
2023
Q2 		$32.4M Sell
577,033
-52,619
-8% -$2.99M 0.01% 1058
2023
Q1 		$28.5M Sell
629,652
-85,776
-12% -$4.17M 0.01% 1099
2022
Q4 		$29.1M Buy
715,428
+48,660
+7% +$2.58M 0.01% 1096
2022
Q3 		$43.6M Buy
666,768
+76,191
+13% +$5.52M 0.01% 829
2022
Q2 		$35.9M Sell
590,577
-23,256
-4% -$1.37M 0.01% 940
2022
Q1 		$38.5M Buy
613,833
+21,096
+4% +$1.32M 0.01% 1025
2021
Q4 		$44.9M Sell
592,737
-72,870
-11% -$6.37M 0.01% 1007
2021
Q3 		$74.5M Buy
665,607
+41,517
+7% +$5.21M 0.02% 742
2021
Q2 		$101M Buy
624,090
+67,829
+12% +$8.25M 0.02% 640
2021
Q1 		$67.8M Sell
556,261
-6,830
-1% -$1.03M 0.02% 798
2020
Q4 		$86.2M Sell
563,091
-9,296
-2% -$1.1M 0.02% 656
2020
Q3 		$47.9M Buy
572,387
+73,909
+15% +$6.56M 0.01% 860
2020
Q2 		$36.6M Buy
498,478
+335,761
+206% +$19.6M 0.01% 1050
2020
Q1 		$6.9M Buy
162,717
+142,557
+707% +$7.36M ﹤0.01% 1742
2019
Q4 		$1.23M Hold
20,160
– – ﹤0.01% 2010
2019
Q3 		$826K Buy
+20,160
New +$963K ﹤0.01% 2043

Other funds holding CRSP

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Norges Bank's CRSP Position: Q3 2026 in Review

Norges Bank sold out of CRISPR Therapeutics (CRSP) in Q3 2026, closing a stake of 270,756 shares — an estimated $14.8M sold.

Norges Bank first reported a position in CRSP in Q3 2019 and held it in 27 quarters. The position peaked at $101M in Q2 2021. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Norges Bank reported no remaining CRISPR Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Norges Bank sold 270,756 CRISPR Therapeutics shares in Q3 2026, an estimated $14.8M.
  • Norges Bank first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 27 quarters.
  • Norges Bank's CRISPR Therapeutics position peaked at $101M in Q2 2021.
  • 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Norges Bank's 13F filing for Q3 2026.